Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter Study of the Safety and Imaging of NTH-2403, a Lutetium-177 Radiolabeled Monoclonal Antibody Targeting the LRRC15 Epitope, in Participants With Locally Advanced or Metastatic Solid Tumors

NCT07272642 is registered in ClinicalTrials.gov with Radiopharm Theranostics, Ltd as lead sponsor.

NCT NCT07272642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07272642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter Study of the Safety and Imaging of NTH-2403, a Lutetium-177 Radiolabeled Monoclonal Antibody Targeting the LRRC15 Epitope, in Participants With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Radiopharm Theranostics, Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
October 31, 2027
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, head and neck squamous cell carcinoma, imaging, non-small cell lung cancer, triple negative breast cancer (tnbc)